Singapore, Republic of Singapore
“Driving better decision-making in healthcare, to achieve better health, better care and better life”
Dr. Daphne Khoo, Executive Director, ACE
History and Structure
The Agency for Care Effectiveness (ACE) was established by the Ministry of Health, Singapore in 2015 to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance and education.
ACE is led by our Executive Director, Dr Daphne Khoo, and comprises three branches:
- The Health Technology Evaluation, Utilisation Review and Adoption (HTA) branch conducts health technology assessments for drugs, vaccines, gene therapies and medical technologies, and develops guidances to encourage adoption of health technology recommendations by public healthcare institutions. It conducts value-based pricing negotiations with manufacturers to ensure that prices of patented health technologies are commensurate with the outcomes that these treatments deliver to patients and the Singapore health system. It also undertakes utilisation review and outcomes evaluation to systematically measure the impact of HTA in Singapore.
- The Evidence to Practice Office supports healthcare professionals and patients in effective, evidence-based care through the development and implementation of clinical guidances as well as professional and patient education initiatives.
- The Planning and Policy branch oversees the strategic planning, corporate finance and administration, as well as the local and international collaborations for ACE’s development. The branch also formulates and executes marketing and communication strategies to build ACE’s brand and credibility as a trusted source of information for both healthcare providers and patients, and develops and implements adoption strategies to drive the uptake of ACE medical technology guidance by collaborating with internal and external stakeholders.
ACE’s mission is to issue objective and credible healthcare guidance, enable stakeholders to optimise health benefits within finite resources, and advance the values of evidence-based practice and appropriate care.
How ACE Works
ACE systematically evaluates health technologies, such as drugs, vaccines, gene therapies and medical technologies, using established HTA methods. This includes using analytical frameworks and drawing on clinical, epidemiological and health economic information to determine how to best allocate Singapore’s limited healthcare resources. ACE also negotiates prices for health technologies under evaluation with manufacturers based on proven outcomes to determine what fair prices should be. ACE’s evaluations equip policy makers in the Ministry of Health, Singapore, with objective and credible evidence to guide national subsidy decisions on health technologies, so that patients have access to good value care earlier.
ACE publishes concise, evidence-based clinical guidances to inform specific areas of clinical practice and serve as a common starting point nationally for clinical decision-making. In addition, ACE conducts Singapore’s first nationwide educational visiting service for healthcare professionals, to further assist them and their patients in integrating current evidence into care, including through shared decision-making.
Information dissemination is fundamental to maximising the impact of ACE’s work. ACE uses various forms of engagement strategies to reach out to stakeholders for their feedback and support at critical touch points during the HTA process from evaluation to implementation. This includes scoping workshops, mass briefings and roadshows, one-to-one consultations, circulars and publication of guidances on the ACE website.
Completed HTA Reports
The methods and processes that are used to guide ACE’s evaluations of drugs and medical technologies, and information on completed HTA evaluations, clinical guidances and subsidy recommendations, may be obtained at our website (www.ace-hta.gov.sg).
Current Projects (A Selection)
Information on completed HTA evaluations and clinical guidances may be obtained at our website (www.ace-hta.gov.sg).
ACE is piloting a company-led submission process in 2021 to allow pharmaceutical companies to prepare evidence submissions to inform subsidy decisions for their products. Procedures and guidelines that companies are expected to follow when preparing their submissions are available at our website (www.ace-hta.gov.sg).
Description of population served: National
Population served (mil): 5.69 million (as of Jun 2020)
Current HTA budget (mil USD): NA
Permanent staff: 78
Ongoing TA projects: Variable year on year
Director: Dr. Daphne Khoo
Contact person: Ms. Aurelia Tan
Ministry of Health
College of Medicine Building
16 College Road